Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 168
Appendix B Public Meeting Agenda March 13, 2003 Immunization Safety Review Influenza Vaccine and Possible Neurological Complications Hotel Monaco Athens Room, 700 F St., NW Washington, DC 9:00 - 9:15 am Welcome and Opening Remarks Marie McCormick, MD, ScD, Committee Chair 9:15 - 9:45 am Influenza Robert G. Webster, PhD St. Jude Children's Research Hospital 9:45 - 10:15 am Guillain-Barre Syndrome John Griffin, MD The Johns Hopkins University School of Medicine 10:15 - 10:45 am The Yearly Production of Influenza Vaccine Roland Levandowski, MD Food and Drug Administration 10:45 - 11:00 am Break 168
OCR for page 169
APPENDIX B 11:00- 11:30 am 11:30- 12:15 pm 12:15 - 1:30 pm 1:30 - 2:15 pm 169 VAERS Reports Related to Influenza Vaccine Penina Haber,MPH Centers for Disease Control and Prevention Discussion Lunch Studies of Guillain-Barre Syndrome After Influenza Vaccination Robert Chen, MD Centers for Disease Control and Prevention 2:15 - 2:45 pm Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines Tamar Lasky, PhD National Institute of Child Health & Human Development 2:45 - 3:15 pm Safety of Influenza Vaccine in the Pediatric Population Eric K. France, MD, MSPH Preventive Medicine Kaiser Permanente Colorado 3:15 - 3:30 pm Break 3:30 - 4:00 pm Intranasal Vaccines Kathryn Edwards, MD, (presented via conference call) Vanderbilt University School of Medicine 4:00 - 4:30 pm VSD Data Related to Influenza Vaccine and Incidence/Relapse of MS Frank DeStefano, MD Centers for Disease Control and Prevention 4:30 - 4:45 pm Use of Medicare Data to Evaluate Adverse Events After Influenza Vaccine Dale Burwen, MD, Food and Drug Administration 4:45 - 5:30 pm Discussion and Public Comment 5:30 pm Adjourn
Representative terms from entire chapter: